Safety of Continuous Anticoagulation With Dabigatran During Implantation of Cardiac Rhythm Devices
| Autor: | William W. Brabham, J. Lacy Sturdivant, J. Marcus Wharton, Darren S. Sidney, Michael R. Gold, Christopher P. Rowley, Robert B. Leman, Peter C. Netzler, Michael L. Bernard, Frank Cuoco |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Pacemaker Artificial medicine.medical_specialty medicine.drug_class Comorbidity Antithrombins Dabigatran medicine Humans Prospective Studies Stroke Aged business.industry Anticoagulant Warfarin Perioperative medicine.disease Thrombosis Defibrillators Implantable Surgery Pulmonary embolism Direct thrombin inhibitor Anesthesia beta-Alanine Benzimidazoles Female Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | The American Journal of Cardiology. 111:1165-1168 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2012.12.046 |
| Popis: | The perioperative bleeding risk associated with therapeutic anticoagulation at cardiac implantable electronic device implantation has previously been demonstrated to vary by the specific anticoagulant used. Although uninterrupted anticoagulation with warfarin appears to be safe, heparin products have been shown to increase the risk of perioperative bleeding. However, the risk associated with cardiac implantable electronic device implantation with anticoagulation using dabigatran, a novel oral direct thrombin inhibitor, is not known. We performed a prospective observational study of patients receiving dabigatran for anticoagulation who underwent cardiac implantable electronic device implantation from June 2011 through May 2012. The study end points included thromboembolic and bleeding complications within 30 days of surgery. Major bleeding complications were defined as bleeding requiring surgical intervention, prolongation of hospitalization, and discontinuation of the anticoagulant or transfusion of blood products within 30 days of surgery. Minor bleeding complications included the development of a hematoma not requiring additional intervention. The thrombotic end points included stroke, transient ischemic attack, myocardial infarction, pulmonary embolism, and deep vein thrombosis. A total of 25 patients were identified for inclusion. During the index hospitalization, no thromboembolic or bleeding complications developed. No major bleeding complications occurred within 30 days of surgery. One minor bleeding event (4%) occurred within 30 days of surgery in 1 patient who was also receiving dual antiplatelet therapy. In conclusion, although no thromboembolic or major bleeding events were observed, additional studies are required to define the optimal antithrombotic management in the perioperative period. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect